Capricor Therapeutics

CAPR

Market cap $1.11B

The semiconductor rotation and memory stock profit taking puts investors in a bind trying to call the top.

Capricor Therapeutics Inc. (NASDAQ:CAPR) stock is trading lower on Friday, down by 13%.

–Advisory Committee meeting scheduled for July 29, 2026– –Company's Biologics License Application on track with PDUFA target action date of August 22, 2026–

SAN DIEGO, June 26, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced positive five-year data from its ongoing HOPE-2 Open-Label Extension (OLE) study of Deramiocel, the Company's lead cell therapy candidate for Duchenne Muscular Dystrophy (DMD). The data will be presented at the Parent Project Muscular Dystrophy (PPMD) 2026 Annual Conference, taking place June 25-27, 2026, in Orlando, Florida, alongside previously reported results from the Company's HOPE-3 Phase 3 trial.

Toronto, Ontario--(Newsfile Corp. - June 19, 2026) - Caprock Mining Corp. (CSE: CAPR) ("Caprock" or the "Company") is pleased to announce that it has closed its previously announced non-brokered private placement offering of 6,000,000 flow-through shares (the "FT Shares") at a price of $0.10 per FT Share for aggregate gross proceeds of $600,000 (the "Offering"). The Offering was initially announced in the Company's press release dated June 12, 2026.

Toronto, Ontario--(Newsfile Corp. - June 17, 2026) - Frank Guillemette (the "Acquiror") announces that, on June 12, 2026, he acquired an aggregate of 200,000 common shares in the capital of Caprock Mining Corp. (CSE: CAPR) ("Caprock" or the "Issuer") through the facilities of the Canadian Securities Exchange for total consideration of $19,136.00 CAD (the "Acquisition"). Immediately prior to the Acquisition, the Acquiror held 20,602,166 common shares and 4,633,333 common share purchase warrants of the Issuer, representing approximately 19.35% of Caprock's issued and outstanding common shares assuming exercise of the common share purchase warrants held by the Acquiror.

Toronto, Ontario--(Newsfile Corp. - June 12, 2026) - Caprock Mining Corp. (CSE: CAPR) ("Caprock" or the "Company") is pleased to announce a proposed non-brokered private placement offering of up to 6,000,000 flow-through shares (the "FT Shares") at a price of $0.10 per FT Share for aggregate gross proceeds of up to $600,000 (the "Offering"). The Company may, in its discretion and subject to the approval of the Canadian Securities Exchange (the "CSE"), increase the size of the Offering.

Toronto, Ontario--(Newsfile Corp. - June 12, 2026) - Caprock Mining Corp. (CSE: CAPR) ("Caprock", or the "Company") is pleased to announce high-grade assay results for the final three drill holes from the recently concluded deep drilling campaign at its flagship Destiny gold property ("Destiny", or the "Property", or the "Project"), located near Val d'Or, Quebec. Key Assay Highlights from the Final 3 Deep Drill Holes: DES-26-184W1: Intersected 8.32 g/t Au over 2.6m and 6.43 g/t Au over 1.8m.

Capricor Therapeutics NASDAQ: CAPR executives said the company is in active discussions with the U.S. Food and Drug Administration as it works toward a potential approval decision for deramiocel, its allogeneic cardiac-derived cell therapy for Duchenne muscular dystrophy.

Capricor Therapeutics, Inc. (CAPR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript